Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. These mutations can cause cells to stop producing functional proteins, potentially leading to serious inherited disorders.

The company’s lead program, ELX-02, was a synthetic aminoglycoside designed to promote ribosomal read-through of premature stop signals in messenger RNA. Eloxx evaluated ELX-02 in clinical development for genetic conditions including cystinosis and explored its potential in other diseases involving nonsense mutations.

Eloxx also developed ZKN-013, an oral small-molecule program intended to address nonsense-mutation disorders. The company’s research and development activities centered on precision medicines for rare diseases, with clinical and regulatory work directed primarily toward the United States and other major biopharmaceutical markets. Eloxx Pharmaceuticals was historically listed on the Nasdaq under the symbol ELOX.

Key Stats

• Today's Range: $12.21 to $13.23
• 50-Day Range: $12.21 to $20.98
• 52-Week Range: $8.20 to $23.40
• Volume: 12,549 shs
• Average Volume: 23,491 shs
• Market Capitalization: $49.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.33
• Consensus Rating: Buy

Eloxx Pharmaceuticals Stock Analysis - MarketRank™

Eloxx Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 411th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Eloxx Pharmaceuticals has a consensus price target of $38.33, representing about 214.0% upside from its current price of $12.21.

Amount of Analyst Coverage

Eloxx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.80% of the float of Eloxx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eloxx Pharmaceuticals has a short interest ratio ("days to cover") of 2.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eloxx Pharmaceuticals has recently increased by 18.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eloxx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eloxx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Eloxx Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: 781-577-5300
• Fax: 908-864-4440
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eloxx Pharmaceuticals: $38.33
• High Price Target: $43.00
• Low Price Target: $32.00
• Potential Upside/Downside: +214.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $6.36 million
• Price / Sales: 7.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($85.17) per share
• Price / Book: -0.14

Miscellaneous

• Outstanding Shares: 4,040,000
• Free Float: 2,991,000
• Market Cap: $49.33 million
• Optionable: N/A
• Beta: -1,960.42